GET DAILY SIGNALSCencora (COR) Delivers Fiscal Q4 Beat as Specialty Shift Accelerates
Key Takeaways
- Cencora reported fiscal fourth-quarter revenue of $88.4 billion, up 5.5% year over year and slightly above consensus estimates.
- Adjusted diluted earnings per share reached $4.66, a 21.4% increase and ahead of the roughly $4.56 consensus.
- GAAP diluted EPS was $2.71, compared with a loss of $1.75 per share in the prior-year quarter.
- Full-year fiscal 2026 revenue climbed 5.0% to $337.4 billion, while adjusted diluted EPS rose 12.3% to $17.97.
- The company raised its quarterly dividend by 10% to $0.66 per share and introduced fiscal 2027 adjusted EPS guidance of $19.40 to $19.75.
- For more detail on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
- Discover automated trading ideas by exploring Tickeron's Trending AI Robots.
Why These Results Matter
Cencora, one of the world's largest pharmaceutical distributors, closed its fiscal year with record results that highlight its accelerating shift toward higher-margin specialty pharmaceuticals and provider services. The quarter ending September 30, 2026, was the first full period to reflect the February 2026 acquisition of OneOncology, a community oncology network that strengthens Cencora's specialty and provider footprint. Investors are closely watching whether specialty momentum can offset the thinner margins of traditional drug distribution and growing demand for GLP-1 medications used for diabetes and weight loss. With management realigning the company into two new reporting segments and issuing initial fiscal 2027 guidance, this report offers a clearer view of Cencora's growth trajectory and capital-allocation priorities.
The Quarter's Reported Numbers
Cencora reported fiscal fourth-quarter revenue of $88.4 billion, up 5.5% year over year and modestly above consensus estimates. Adjusted diluted EPS was $4.66, a 21.4% increase that beat the consensus of approximately $4.56. GAAP diluted EPS was $2.71, compared with a loss of $1.75 per share a year earlier. Consolidated adjusted operating income rose 22.1%, driven by specialty sales to health systems and physician practices, continued GLP-1 demand, and the OneOncology contribution, partly offset by manufacturer list-price reductions and lower sales to a large mail-order customer. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the full fiscal year, revenue increased 5.0% to $337.4 billion, while adjusted diluted EPS climbed 12.3% to $17.97. Management also declared a 10% dividend increase to $0.66 per share and initiated fiscal 2027 adjusted EPS guidance of $19.40 to $19.75, implying 8% to 10% growth, with revenue growth projected at 3% to 5%.
Market Reaction and Sentiment
Cencora shares traded higher in intraday trading on November 4, 2026, following the report, reflecting investor approval of the earnings beat, margin expansion, and the dividend increase. Sentiment was tempered, however, by fiscal 2027 guidance that came in below the roughly 14% EPS growth figure some analysts had previously referenced, as management pointed to divestiture-related dilution and acquisition-related factors. Investors also reacted to the company's announcement of a new organizational structure and an agreement to acquire American Oncology Network, signaling continued execution on its specialty-focused strategy. The mix of a strong operational quarter against a more conservative near-term outlook defined the day's balanced market response.
Forward Outlook and Factors to Watch
Cencora enters fiscal 2027 with a restructured organization built around two segments: Specialty Pharmaceutical and Provider Services, and Pharmaceutical Distribution and Services. Management reiterated long-term targets of 7% to 10% adjusted operating income growth and 10% to 14% adjusted EPS growth, while setting segment-specific expectations for mid-single-digit and mid-teens operating income growth, respectively.
Investors should monitor several factors in the coming quarters. The integration and performance of OneOncology, along with the pending American Oncology Network acquisition, will test Cencora's ability to scale its provider-services platform. Specialty distribution revenue is expected to approach roughly $100 billion in fiscal 2027, a key indicator of the shift toward higher-margin therapies.
Margin dynamics also warrant attention, as accelerating GLP-1 volumes and manufacturer list-price reductions can pressure gross margins even as revenue grows. The planned merger of MWI Animal Health and the sale of the Profarma equity stake add complexity to the fiscal 2027 outlook. Finally, interest expense tied to acquisition financing and any further capital-return actions will shape bottom-line growth. Investors will look for evidence that specialty momentum and disciplined capital allocation can sustain the company's long-term growth algorithm.
One Tool I Rely On for Deeper Analysis
When evaluating earnings like these, I often use Tickeron’s AI Screener to scan for comparable names and refine my view on sector trends. The platform lets me apply technical patterns, fundamentals, and AI signals in one place, which saves time and surfaces ideas I might otherwise miss. It has become a regular part of how I cross-check company results against peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
COR in upward trend: 10-day moving average broke above 50-day moving average on October 14, 2026
The 10-day moving average for COR crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on COR as a result. In 54 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for COR just turned positive on November 04, 2026. Looking at past instances where COR's MACD turned positive, the stock continued to rise in 33 of 53 cases over the following month. The odds of a continued upward trend are 62%.
COR moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for COR moved above the 200-day moving average on October 01, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +4.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where COR advanced for three days, in 235 of 384 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 229 of 350 cases where COR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The 10-day RSI Indicator for COR moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator moved out of overbought territory. In 20 of the 49 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 72 cases where COR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 46%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
COR broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 13 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 21 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. COR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.863) is normal, around the industry mean (14.461). P/E Ratio (24.653) is within average values for comparable stocks, (11.207). Projected Growth (PEG Ratio) (0.636) is also within normal values, averaging (2.016). Dividend Yield (0.007) settles around the average of (0.134) among similar stocks. P/S Ratio (0.187) is also within normal values, averaging (4.260).
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a real estate investment trust
Industry MedicalDistributors
Advertisement